Senior Management

Robert J. Hugin

Chairman and Chief Executive Officer

Bob Hugin

Mr. Hugin has been our Chief Executive Officer since June 2010 and our Chairman since June 2011. He was previously President and Chief Operating Officer from May 2006 to June 2010, and was elected by the Board of Directors to serve as a Director in December 2001. Mr. Hugin served as Senior Vice President and Chief Financial Officer from June 1999 to May 2006. Mr. Hugin is immediate past Chairman of the Board of The Pharmaceutical Research and Manufacturers of America and is a member of the Board of Trustees of Princeton University, The Medicines Company, and The Darden Foundation, University of Virginia. He also serves as a member of the Board of Trustees of Atlantic Health System and of Family Promise, a national non-profit network assisting homeless families. Prior to joining Celgene, Mr. Hugin was a Managing Director with J.P. Morgan & Co. Inc. Mr. Hugin received an AB degree from Princeton University in 1976 and an MBA from the University of Virginia in 1985 and served as a United States Marine Corps infantry officer during the intervening period.

Story on Robert Hugin from The Street

Mark J. Alles

President and Chief Operating Officer

Mark Alles

Mr. Alles became President and Chief Operating Officer in August 2014. He was formerly the Executive Vice President and Global Head of Hematology and Oncology since December 2012 following his promotion to Executive Vice President and Chief Commercial Officer on February 15, 2012. Mr. Alles joined Celgene in April 2004 and served as Vice President, Global Marketing until March 2009 when he became President of the Americas Region. Responsibility for commercial operations in Japan and the Asia Pacific Region was added in July 2011. Mr. Alles previously served as Vice President for the U.S. Oncology Business Unit of Aventis Pharmaceuticals and in other commercial sales and marketing management roles over an 11-year period with Aventis. After earning his BS degree from Lock Haven University of Pennsylvania and serving as a Captain in the United States Marine Corps, Mr. Alles started his 27-year career in the pharmaceutical industry at Bayer and worked at Centocor before its acquisition by Johnson & Johnson. Mr. Alles currently serves as a Director for Gilda’s Club NYC, a not-for-profit organization helping people with cancer, and as a trustee of The Healthcare Institute of New Jersey.

Thomas O. Daniel, MD

Executive Vice President and President, Celgene Research and Early Development

Thomas_Daniel

Dr. Daniel is Executive Vice President and President, Celgene Research and Early Development. He formerly served as Chief Scientific Officer and Director of Ambrx Inc., and as Vice President, Research at Amgen Inc., where he was Research Site Head of Amgen Washington and Therapeutic Area Head of Inflammation. Prior to Amgen’s acquisition of Immunex, Dr. Daniel served as Senior Vice President of Discovery Research. He serves on the Board of Directors of The Pharmaceutical Research and Manufacturers of America (PhRMA) Foundation, and is a member of the PhRMA Biomedical Advisory Committee. He is a Director of FerruMax, Abide, and PharmAkea, all privately held biotechnology companies. Dr. Daniel serves as a member of the Biomedical Science Advisory Board of Vanderbilt University Medical Center and is a member of the Therapeutic Advisory Board of aTyr Pharma, Inc, a privately held biotechnology company. A nephrologist and former academic investigator, Dr. Daniel was previously the K.M. Hakim Professor of Medicine and Cell Biology at Vanderbilt University, and Director of the Vanderbilt Center for Vascular Biology. He formerly conducted research supported by the NIH and the Howard Hughes Medical Institute at UC San Francisco, earned an MD from the University of Texas, Southwestern, and completed his medical residency at Massachusetts General Hospital.

Jacqualyn A. Fouse, PhD

President, Global Hematology and Oncology

Jacqualyn Fouse

Dr. Fouse was promoted to President, Global Hematology and Oncology in August 2014. She was most recently Executive Vice President and Chief Financial Officer. Dr. Fouse joined Celgene as Senior Vice President and Chief Financial Officer in September 2010. She previously served as Chief Financial Officer for Bunge Ltd., an NYSE-listed, leading global agribusiness and food company. Prior to that, Dr. Fouse served as Senior Vice President, Chief Financial Officer and Corporate Strategy, at Alcon Laboratories, Inc. Prior to Alcon, Dr. Fouse was Chief Financial Officer of the Swissair Group in Switzerland from 2001 to 2002, and she was Group Treasurer of Nestle S.A. in Switzerland from 1999 to 2001. Dr. Fouse previously held various senior level financial positions in both the U.S. and Switzerland with both Alcon and Nestle from 1986 to 1999. She also held positions with LTV Aerospace and Defense and Celanese Chemical Company from 1983 to 1986. Dr. Fouse serves on the Board of Directors of Dick’s Sporting Goods and is a member of the Board of Directors for Perrigo. Dr. Fouse holds BA and MA degrees in Economics and a PhD in Finance from the University of Texas at Arlington. She serves on the Development Board of UTA as well as the Advisory Board of the College of Business Administration and on the Advisory Board of Texas Christian University.

Perry A. Karsen

Chief Executive Officer of Celgene Cellular Therapeutics

Perry_karsen

Mr. Karsen serves the Chief Executive Officer of Celgene Cellular Therapeutics (CCT), the placental stem cell research and development division of the Company. Previously he was Executive Vice President, Chief Executive Officer of CCT and Chief Operations Officer. Mr. Karsen served as President and Chief Executive Officer at Pearl Therapeutics, a privately-held biotechnology company, from February 2009 until July 2010. From 2004 to 2009, Mr. Karsen was Senior Vice President and Head of Worldwide Business Development for Celgene and was also responsible for emerging businesses as President, Asia/Pacific Region. Prior to his tenure with Celgene, Mr. Karsen held executive positions at Human Genome Sciences, Bristol-Myers-Squibb, Genentech and Abbott Laboratories. In addition, Mr. Karsen served as a General Partner at Pequot Ventures. Mr. Karsen serves as a member of the Board of Directors of the Biotechnology Industry Organization (BIO) and a member of the Board of Directors for the Life Sciences Foundation. In addition, Mr. Karsen is a member of the Board of Directors of Agios Pharmaceuticals, a publicly-held biotechnology company, Alliqua Biomedical, a publicly-held advanced wound management company, and Navidea Biopharmaceuticals, a publicly-held precision diagnostics company. Mr. Karsen has a Masters of Management degree from Northwestern University’s Kellogg Graduate School of Management, a Masters in Teaching of Biology from Duke University, and a BS in Biological Sciences from the University of Illinois, Urbana-Champaign.

Peter N. Kellogg

Executive Vice President and Chief Financial Officer

Peter N. Kellogg

Mr. Kellogg was named Executive Vice President and Chief Financial Officer in August 2014. Mr. Kellogg joined Celgene as Executive Vice President in July 2014. Previously, he was Chief Financial Officer and Executive Vice President of Merck & Co. Inc. since August 2007. From 2000 to 2007, Mr. Kellogg served as Chief Financial Officer and Executive Vice President of Finance (since 2003) at Biogen Idec Inc. and the former Biogen, Inc. Before that, he served as Senior Vice President, PepsiCo E-Commerce at PepsiCo Inc. from March to July 2000 and as Senior Vice President and Chief Financial Officer, Frito-Lay International, from March 1998 to March 2000. From 1987 to 1998, he served in a variety of senior financial, international and general management positions at PepsiCo and the Pepsi-Cola International, Pepsi-Cola North America, and Frito-Lay International divisions. Prior to joining PepsiCo, Mr. Kellogg was a senior consultant with Arthur Andersen & Co. and Booz Allen & Hamilton. Since March 2007, Mr. Kellogg has been a Director of Metabolix, Inc., a public bioscience and engineering company focused on providing sustainable solutions to the plastics and chemicals industries. He received a BSE from Princeton University in 1978 and an MBA from The Wharton School in 1982.

Scott A. Smith

President, Global Inflammation and Immunology

Scott Smith

Mr. Smith was named President, Global Inflammation and Immunology (I & I) in August 2014. Previously he was Senior Vice President, Global Head of I & I. He joined Celgene in 2008 as Vice President, Global Marketing Inflammation and Immunology. From 2003 to 2008 Mr. Smith was with Biovail, holding positions of General Manager Biovail U.S., General Manager Biovail Canada and Global Commercial Head. As Global Commercial Head for Biovail, he was responsible for global revenue generation, global commercial strategies, business development strategy, and input into global regulatory and clinical development strategies. Prior to Biovail, Mr. Smith was with Pharmacia/Upjohn for 16 years where he held various positions including Vice President U.S. Sales, Vice President Marketing Europe based in Paris, Vice President and Commercial Lead for Canada based in Toronto, and Commercial and Regulatory Head for South East Asia based in Hong Kong. Mr. Smith holds a BSc in Chemistry and an HBSc in Pharmacology and Toxicology from the University of Western Ontario and a Masters of International Business Management from the American Graduate School of International Management (Thunderbird).

Lawrence V. Stein

Executive Vice President, General Counsel and Corporate Secretary

Lawrence_Stein

Mr. Stein joined Celgene as Executive Vice President, General Counsel and Corporate Secretary in November 2012. From March 2010 through March 2012, Mr. Stein served as Counsel to Reed Smith LLP. He joined Wyeth’s legal team in 1997 and served as Senior Vice President and General Counsel from 2003 until Wyeth’s merger with Pfizer, Inc. in 2009. While at Wyeth, he served on the Board of Directors of Immunex Corporation and until December 2012 served on the Board of Trustees of the Wistar Institute. Prior to joining Wyeth, he was Senior Vice President, General Counsel and Secretary of Genetics Institute, Inc. Mr. Stein started his legal career with the law firm of Arnold & Porter where he specialized in the representation of pharmaceutical and medical device companies with respect to regulatory matters and product liability litigation. He received his JD from the University of Pennsylvania Law School, an AB from Columbia College and an MA from Cornell University.